Concepts (94)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Breast Neoplasms | 14 | 2024 | 1723 | 0.830 |
Why?
|
| Phyllodes Tumor | 1 | 2015 | 1 | 0.460 |
Why?
|
| Upper Extremity | 2 | 2018 | 15 | 0.260 |
Why?
|
| Healthcare Disparities | 2 | 2024 | 590 | 0.200 |
Why?
|
| Lymphedema | 1 | 2020 | 7 | 0.170 |
Why?
|
| Education, Medical, Undergraduate | 1 | 2021 | 95 | 0.170 |
Why?
|
| Quality Indicators, Health Care | 2 | 2010 | 49 | 0.160 |
Why?
|
| Students, Medical | 1 | 2021 | 158 | 0.150 |
Why?
|
| Quality of Health Care | 2 | 2010 | 161 | 0.150 |
Why?
|
| Mastectomy, Segmental | 2 | 2016 | 25 | 0.150 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 2 | 2015 | 13 | 0.140 |
Why?
|
| Mastectomy | 1 | 2018 | 21 | 0.140 |
Why?
|
| Retrospective Studies | 5 | 2021 | 2544 | 0.140 |
Why?
|
| Follow-Up Studies | 6 | 2018 | 1067 | 0.120 |
Why?
|
| Lymph Node Excision | 1 | 2016 | 25 | 0.120 |
Why?
|
| Neoplasm, Residual | 1 | 2015 | 17 | 0.120 |
Why?
|
| Carcinoma, Ductal, Breast | 1 | 2015 | 31 | 0.120 |
Why?
|
| Middle Aged | 10 | 2018 | 12222 | 0.110 |
Why?
|
| Hospitals, Public | 2 | 2015 | 14 | 0.110 |
Why?
|
| Population Surveillance | 1 | 2016 | 246 | 0.110 |
Why?
|
| Female | 13 | 2024 | 24698 | 0.110 |
Why?
|
| Postoperative Complications | 1 | 2016 | 263 | 0.110 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2015 | 154 | 0.110 |
Why?
|
| Aged | 8 | 2015 | 8214 | 0.100 |
Why?
|
| Humans | 17 | 2024 | 43102 | 0.100 |
Why?
|
| Pain | 1 | 2016 | 290 | 0.100 |
Why?
|
| Angiomatosis | 1 | 2012 | 1 | 0.090 |
Why?
|
| Breast Diseases | 1 | 2012 | 5 | 0.090 |
Why?
|
| Hyperplasia | 1 | 2012 | 39 | 0.090 |
Why?
|
| Carcinoma | 1 | 2013 | 108 | 0.090 |
Why?
|
| Receptors, Progesterone | 2 | 2012 | 92 | 0.090 |
Why?
|
| Adult | 8 | 2018 | 13872 | 0.090 |
Why?
|
| Receptors, Estrogen | 2 | 2012 | 183 | 0.090 |
Why?
|
| Prognosis | 3 | 2020 | 861 | 0.090 |
Why?
|
| Breast | 1 | 2012 | 139 | 0.080 |
Why?
|
| Mammography | 2 | 2012 | 212 | 0.080 |
Why?
|
| Colorectal Neoplasms | 2 | 2005 | 512 | 0.070 |
Why?
|
| Patient Advocacy | 1 | 2008 | 22 | 0.070 |
Why?
|
| Prospective Studies | 3 | 2018 | 1600 | 0.070 |
Why?
|
| Socioeconomic Factors | 3 | 2024 | 1234 | 0.070 |
Why?
|
| Arm | 2 | 2020 | 28 | 0.070 |
Why?
|
| Neoplasm Invasiveness | 3 | 2015 | 290 | 0.070 |
Why?
|
| Continuity of Patient Care | 1 | 2008 | 120 | 0.060 |
Why?
|
| Patient Compliance | 1 | 2008 | 233 | 0.060 |
Why?
|
| Health Services Accessibility | 3 | 2024 | 706 | 0.060 |
Why?
|
| Reproducibility of Results | 2 | 2020 | 1081 | 0.060 |
Why?
|
| Gene Products, nef | 1 | 2005 | 19 | 0.060 |
Why?
|
| Health Education | 1 | 2008 | 363 | 0.060 |
Why?
|
| Mass Screening | 1 | 2008 | 541 | 0.050 |
Why?
|
| DNA, Mitochondrial | 1 | 2004 | 191 | 0.050 |
Why?
|
| Physical Examination | 1 | 2021 | 45 | 0.040 |
Why?
|
| Problem-Based Learning | 1 | 2021 | 42 | 0.040 |
Why?
|
| Radionuclide Imaging | 1 | 2021 | 29 | 0.040 |
Why?
|
| Aged, 80 and over | 3 | 2015 | 2853 | 0.040 |
Why?
|
| Neoplasm Staging | 2 | 2015 | 374 | 0.040 |
Why?
|
| Learning | 1 | 2021 | 161 | 0.040 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2021 | 94 | 0.040 |
Why?
|
| Curriculum | 1 | 2021 | 318 | 0.040 |
Why?
|
| Hospitals, Urban | 2 | 2008 | 42 | 0.040 |
Why?
|
| Medical Oncology | 2 | 2008 | 50 | 0.030 |
Why?
|
| Axilla | 1 | 2016 | 6 | 0.030 |
Why?
|
| Sentinel Lymph Node Biopsy | 1 | 2016 | 7 | 0.030 |
Why?
|
| Range of Motion, Articular | 1 | 2016 | 37 | 0.030 |
Why?
|
| Exercise Therapy | 1 | 2016 | 87 | 0.030 |
Why?
|
| Cross-Sectional Studies | 2 | 2018 | 3156 | 0.030 |
Why?
|
| Pain Measurement | 1 | 2016 | 183 | 0.030 |
Why?
|
| Models, Theoretical | 1 | 2016 | 232 | 0.030 |
Why?
|
| Longitudinal Studies | 1 | 2018 | 1063 | 0.030 |
Why?
|
| Patient Education as Topic | 1 | 2016 | 235 | 0.030 |
Why?
|
| Pleural Effusion, Malignant | 1 | 2013 | 7 | 0.020 |
Why?
|
| Soft Tissue Neoplasms | 1 | 2013 | 15 | 0.020 |
Why?
|
| Perimenopause | 1 | 2012 | 7 | 0.020 |
Why?
|
| Cancer Care Facilities | 1 | 2010 | 20 | 0.020 |
Why?
|
| Young Adult | 2 | 2012 | 5080 | 0.020 |
Why?
|
| Adolescent | 2 | 2012 | 6081 | 0.020 |
Why?
|
| Community Networks | 1 | 2008 | 107 | 0.020 |
Why?
|
| Social Class | 1 | 2008 | 291 | 0.020 |
Why?
|
| Pilot Projects | 1 | 2008 | 760 | 0.010 |
Why?
|
| Neoplasms, Experimental | 1 | 2005 | 38 | 0.010 |
Why?
|
| Transplantation, Heterologous | 1 | 2005 | 98 | 0.010 |
Why?
|
| Social Support | 1 | 2008 | 445 | 0.010 |
Why?
|
| Mice, SCID | 1 | 2005 | 158 | 0.010 |
Why?
|
| nef Gene Products, Human Immunodeficiency Virus | 1 | 2005 | 59 | 0.010 |
Why?
|
| DNA, Neoplasm | 1 | 2004 | 92 | 0.010 |
Why?
|
| Prevalence | 1 | 2008 | 1612 | 0.010 |
Why?
|
| Disease Progression | 1 | 2004 | 667 | 0.010 |
Why?
|
| Genetic Variation | 1 | 2004 | 430 | 0.010 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2008 | 989 | 0.010 |
Why?
|
| HIV-1 | 1 | 2005 | 755 | 0.010 |
Why?
|
| Cell Proliferation | 1 | 2005 | 1455 | 0.010 |
Why?
|
| Apoptosis | 1 | 2005 | 1568 | 0.010 |
Why?
|
| Mice | 1 | 2005 | 6644 | 0.010 |
Why?
|
| Male | 1 | 2012 | 23409 | 0.010 |
Why?
|
| Animals | 1 | 2005 | 16992 | 0.000 |
Why?
|